Summary
24.97 0.06(0.22%)07/03/2024
Bridgebio Pharma LLC (BBIO)
Bridgebio Pharma LLC (BBIO)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.12 | 5.94 | -13.85 | -14.59 | -34.04 | 43.89 | -12.74 | -9.38 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 24.97 | |
| Open | 25.02 | |
| High | 25.48 | |
| Low | 24.71 | |
| Volume | 894,928 | |
| Change | 0.03 | |
| Change % | 0.12 | |
| Avg Volume (20 Days) | 2,440,586 | |
| Volume/Avg Volume (20 Days) Ratio | 0.37 | |
| 52 Week Range | 16.62 - 44.32 | |
| Price vs 52 Week High | -43.67% | |
| Price vs 52 Week Low | 50.21% | |
| Range | -0.22 | |
| Gap Up/Down | -0.69 | |
Fundamentals | ||
| Market Capitalization (Mln) | 4,678 | |
| EBIDTA | -239,619,008 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 81.20 | |
| Book Value | 3.9180 | |
| Earnings Per Share | -3.8850 | |
| EPS Estimate Current Quarter | -0.9000 | |
| EPS Estimate Next Quarter | -0.9200 | |
| EPS Estimate Current Year | -3.6900 | |
| EPS Estimate Next Year | -3.8100 | |
| Diluted EPS (TTM) | -3.8850 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -9.3975 | |
| Return on asset (TTM) | -0.4263 | |
| Return on equity (TTM) | -17.8967 | |
| Revenue TTM | 56,952,000 | |
| Revenue per share TTM | 0.4130 | |
| Quarterly Revenue Growth (YOY) | -0.7120 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 8,249,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 123.6828 | |
| Revenue Enterprise Value | 107.5645 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 147,184,992 | |
| Shares Float | 70,254,379 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 7.36 | |
| Institutions (%) | 96.08 | |
07/02 11:15 EST - prnewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
NEW YORK , July 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. ("BridgeBio" or the "Company") (NASDAQ: BBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
NEW YORK , July 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. ("BridgeBio" or the "Company") (NASDAQ: BBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
06/24 18:15 EST - accesswire.com
Levi & Korsinsky Reminds BridgeBio Investors of the Ongoing Investigation into Potential Violations of Securities Laws - BBIO
NEW YORK, NY / ACCESSWIRE / June 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violations of federal securities laws. BridgeBio issued a press release on June 4, 2024, "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile.
Levi & Korsinsky Reminds BridgeBio Investors of the Ongoing Investigation into Potential Violations of Securities Laws - BBIO
NEW YORK, NY / ACCESSWIRE / June 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violations of federal securities laws. BridgeBio issued a press release on June 4, 2024, "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile.
06/24 18:15 EST - accesswire.com
BridgeBio Pharma, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - BBIO
NEW YORK, NY / ACCESSWIRE / June 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violations of federal securities laws. BridgeBio issued a press release on June 4, 2024, "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile.
BridgeBio Pharma, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - BBIO
NEW YORK, NY / ACCESSWIRE / June 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violations of federal securities laws. BridgeBio issued a press release on June 4, 2024, "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile.
06/24 07:20 EST - accesswire.com
Lost Money on BridgeBio Pharma, Inc.(BBIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / June 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violations of federal securities laws. BridgeBio issued a press release on June 4, 2024, "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile.
Lost Money on BridgeBio Pharma, Inc.(BBIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / June 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violations of federal securities laws. BridgeBio issued a press release on June 4, 2024, "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile.
06/22 18:03 EST - accesswire.com
BridgeBio Pharma, Inc. (BBIO) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / June 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violations of federal securities laws. BridgeBio issued a press release on June 4, 2024, "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile.
BridgeBio Pharma, Inc. (BBIO) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / June 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violations of federal securities laws. BridgeBio issued a press release on June 4, 2024, "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile.
06/22 18:01 EST - accesswire.com
BridgeBio Pharma, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - BBIO
NEW YORK, NY / ACCESSWIRE / June 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violations of federal securities laws. BridgeBio issued a press release on June 4, 2024, "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile.
BridgeBio Pharma, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - BBIO
NEW YORK, NY / ACCESSWIRE / June 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violations of federal securities laws. BridgeBio issued a press release on June 4, 2024, "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile.
06/20 11:30 EST - accesswire.com
BridgeBio Pharma, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- BBIO
NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violations of federal securities laws. BridgeBio issued a press release on June 4, 2024, "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile.
BridgeBio Pharma, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- BBIO
NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violations of federal securities laws. BridgeBio issued a press release on June 4, 2024, "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile.
06/20 11:00 EST - accesswire.com
BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BridgeBio Pharma, Inc. ("BridgeBio" or "the Company") (NASDAQ:BBIO). Investors who purchased BridgeBio securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BBIO.
BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BridgeBio Pharma, Inc. ("BridgeBio" or "the Company") (NASDAQ:BBIO). Investors who purchased BridgeBio securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BBIO.
06/20 07:30 EST - accesswire.com
ATTENTION BridgeBio Pharma, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violations of federal securities laws. BridgeBio issued a press release on June 4, 2024, "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile.
ATTENTION BridgeBio Pharma, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violations of federal securities laws. BridgeBio issued a press release on June 4, 2024, "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile.
06/18 16:14 EST - accesswire.com
Lost Money on BridgeBio Pharma, Inc. (BBIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / June 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violations of federal securities laws. BridgeBio issued a press release on June 4, 2024, "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile.
Lost Money on BridgeBio Pharma, Inc. (BBIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / June 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violations of federal securities laws. BridgeBio issued a press release on June 4, 2024, "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile.
06/18 07:30 EST - globenewswire.com
BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
- BridgeBio has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 in individuals living with LGMD2I/R9, with top-line results from the interim analysis expected in 2025
BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
- BridgeBio has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 in individuals living with LGMD2I/R9, with top-line results from the interim analysis expected in 2025
06/13 14:38 EST - globenewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) (NASDAQ: BBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) (NASDAQ: BBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.